2-(Butylamino)-1-[7-chloro-2-(4-chlorophenyl)-6-methylquinolin-4-yl]ethanol | 1027299-40-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 2-(Butylamino)-1-[7-chloro-2-(4-chlorophenyl)-6-methylquinolin-4-yl]ethanol
• CAS: 1027299-40-6
• 化学式: C₂₂H₂₄Cl₂N₂O
• 分子量: 403.351
• InChiKey: SJZRJCMSYQVBQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  45.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-[7-Chloro-2-(4-chlorophenyl)-6-methylquinolin-4-yl]-2-(dibutylamino)ethanol 生成 2-(Butylamino)-1-[7-chloro-2-(4-chlorophenyl)-6-methylquinolin-4-yl]ethanol
  参考文献：
  名称：

  WO2008/60269

  摘要：

  公开号：

文献信息

• Quninoline Methanol Compounds for the Treatment and Prevention of Parasitic Infections
  申请人：Dow Geoffrey

  公开号：US20110092488A1

  公开（公告）日：2011-04-21

  Malaria is responsible for 1-2 million deaths and 300-500 million clinical cases annually and is an ever present problem for the military, tourists and business travelers. Mefloquine is known and used for malaria prophylaxis. However it is associated with neurological effects. The present invention is directed to providing new and novel quinoline analogs that are less neurotoxic than mefloquine without compromising efficacy. The present invention is also directed to the prevention and treatment of other microbial, parasitic, protozoan, bacterial and fungal diseases.
• [EN] QUINOLINE METHANOL COMPOUNDS FOR THE TREATMENT AND PREVENTION OF PARASITIC INFECTIONS<br/>[FR] COMPOSÉS DE QUINOLINE-MÉTHANOL POUR LE TRAITEMENT ET LA PRÉVENTION D'INFECTIONS PARASITAIRES
  申请人：US ARMY

  公开号：WO2008060269A2

  公开（公告）日：2008-05-22

  [EN] Malaria is responsible for 1-2 million deaths and 300-500 million clinical cases annually and is an ever present problem for the military, tourists and business travelers. Mefloquine is known and used for malaria prophylaxis. However it is associated with neurological effects. The present invention is directed to providing new and novel quinoline analogs that are less neurotoxic than mefloquine without compromising efficacy. The present invention is also directed to the prevention and treatment of other microbial, parasitic, protozoan, bacterial and fungal diseases.
  [FR] Le paludisme est responsable de la mort de 1 à 2 millions de personnes et de 300 à 500 millions de cas cliniques annuellement et représente un problème omniprésent pour les militaires, les touristes et ceux qui font des voyages d'affaires. La méfloquine est connue et utilisée pour la prophylaxie du paludisme. Cependant, elle est associée à des effets neurologiques. La présente invention concerne la fourniture de nouveaux analogues de quinoline qui sont moins neurotoxiques que la méfloquine sans compromettre l'efficacité. La présente invention concerne également la prévention et le traitement d'autres maladies microbiennes, parasitaires, protozoaires, bactériennes et fongiques.